COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
Results from this study demonstrate a reduction in the proportion of patients requiring COPD/chronic bronchitis related readmission within 30 days and 12 months of the Aerobika® OPEP device therapy initiation compared to an alternative OPEP device.
This further supports the use of the Aerobika®OPEP device as an add-on to usual care to manage COPD/chronic bronchitis patients post-exacerbation and highlights that not all OPEP devices are the same in terms of 30-day and 12-month readmissions
Results from this study demonstrate a reduction in the proportion of patients requiring COPD/chronic bronchitis related readmission within 30 days and 12 months of the Aerobika® OPEP device therapy initiation compared to an alternative OPEP device.
This further supports the use of the Aerobika® OPEP device as an add-on to usual care to manage COPD/chronic bronchitis patients post-exacerbation and highlights that not all OPEP devices are the same in terms of 30-day and 12-month readmissions
COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA*oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1
The delivery of medication from the AEROECLIPSE* II BAN* to the lungs was not affected by the incorporation of the Aerobika* OPEP device. Aerosol deposition within the lung was unaltered by the addition of the OPEP device as evidenced by the near identical percentage of the dose being deposited in both the peripheral and central airways.
BAN+OPEP therapy could offer the clinician the opportunity for combined treatment thereby reducing the time needed for the patient to take both nebulizer and OPEP treatments separately.
Living a full life with Chronic Obstructive Pulmonary Disease (COPD) is more accessible than ever before with today’s online resources. Whether you’re looking for in-depth tutorials, facts, or simple tips on self-management, the web offers information at your fingertips. Here’s a few of our favourite bookmark-worthy websites for you!
Living a full life with Chronic Obstructive Pulmonary Disease (COPD) is more accessible than ever before with today’s online resources. Whether you’re looking for in-depth tutorials, facts, or simple tips on self-management, the web offers information at your fingertips. Here’s a few of our favourite bookmark-worthy websites for you!
New information regarding the efficiency and effectiveness of different oscillating positive expiratory pressure devices was presented at CHEST 2017 in Toronto, Canada.
